Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03648372 · ClinicalTrials.gov registry record · Phase 1
A Study of TAK-981 in People With Advanced Solid Tumors or Cancers in the Immune System
A Phase 1 study, sponsored by Takeda.
- Terminated
- Registry status
- Phase 1
- Development phase
- 109
- Enrollment target
NCT03648372 is a Phase 1 study that was terminated before completion, run by Takeda. The registered enrollment target is 109 participants.
The verdict
NCT03648372, a Phase 1 study, was terminated before completion, sponsored by Takeda.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 109 participants
- Enrollment target
Study Summary
This study is in 2 parts. The main aims of the 1st part of the study are to check if people with advanced solid tumors or cancers in the immune system (lymphomas) have side effects from TAK-981, and to check how much TAK-981 they can receive without getting side effects from it. The main aims of the 2nd part of the study are to learn if the condition of people with specific cancers improves after treatment with TAK-981. Another aim is to check for side effects from TAK-981. In the 1st part of the study, participants will receive TAK-981. In the 2nd part of the study, participants with specific tumor types will receive TAK-981 at the recommended phase 2 dose determined during the 1st part of the study. In both parts of the study, participants can receive TAK-981 for up to 1 year or longer if their condition stays improved. Participants will receive TAK-981 through vein.
Interventions
- DRUG TAK-981
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 109 participants |
| Start Date | 2018-10-01 |
| Est. Completion | 2023-12-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03648372
The ClinicalTrials.gov registry entry for NCT03648372 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 109 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TAK-981 is the first listed.
NCT03648372 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03648372 about?
NCT03648372 is a clinical study titled "A Study of TAK-981 in People With Advanced Solid Tumors or Cancers in the Immune System". This study is in 2 parts. The main aims of the 1st part of the study are to check if people with advanced solid tumors or cancers in the immune system (lymphomas) have side effects from TAK-981, and to check how much TAK-981 they can receive without getting side effects from it. The main aims of t...
What is the current status of trial NCT03648372?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 109 participants. The study started on 2018-10-01. Estimated completion is 2023-12-14.
What interventions are being tested in trial NCT03648372?
The interventions under investigation include: TAK-981 (DRUG).
Who is sponsoring clinical trial NCT03648372?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.